Abstract: The present invention relates to a method for the production of saccharide preparations, i.e., syrups, by saccharifying a liquefied starch solution, which method comprises a saccharification step during which step one or more enzymatic saccharification stages takes place, and the subsequent steps of one or more high temperature membrane separation steps, and recirculation of the saccharification enzyme, in which method the membrane separation steps are carried out as an integral part of the saccharification step.

Abstract: Insulin preparations of superior physical stability, comprising dissolved and/or precipitated human insulin or an analogue or derivative thereof, and a water-soluble reduced or non-reducing carbohydrate containing at least 4 carbon atoms in the main carbohydrate structure, or a water-soluble non-reducing ester and/or ether derivative of a carbohydrate or reduced carbohydrate containing at least 4 carbon atoms in the main carbohydrate structure, or mixtures thereof are disclosed.

Abstract: The present invention relates to compounds, compositions containing them, and their use for treating medical disorders related to binding to human somatostatin receptor subtypes.

Abstract: The present invention relates to a starch conversion process of the type which includes a debranching step wherein an isoamylase being active at the process conditions prevailing is used for debranching the starch and to the use of thermostable isoamylases for starch conversion. The invention further relates to an isolated isoamylase obtained from a strain of the genus Rhodothermus and to cloned DNA sequences encoding isoamylases derived from a strain of Rhodothermus or Sulfolobus, to expression vectors comprising said DNA sequence, host cells comprising such expression vectors, and finally to methods for producing said isoamylases.

Abstract: The present invention relates to therapeutically active quaternary azacyclic or azabicyclic compounds with formula I: ##STR1## wherein X is oxygen or sulfur and wherein G is selected from the group of azacyclic or azabicyclic ring systems consisting of: ##STR2## a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a cholinergic deficit in the peripheral system.

Abstract: The present invention relates to a compound of general formula I ##STR1## for treating medical disorders related to binding to human somatostatin receptor subtypes.

Abstract: Novel mannanases may be derived from eg Bacillus subtilis strain 168 or may be encoded by polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO: 1. The mannanases are alkaline and are useful e.g. in cleaning compositions, for modifying plant material, and for treatment of cellulosic fibres.

Abstract: This invention is in the field of Bio-Polishing. More specifically, the invention relates to a process for achieving Bio-Polishing effects during the manufacture of cellulosic fabrics.

Abstract: The present invention relates to a process for producing a therapeutic powder formulation, comprising (a) providing an acidic aqueous solution comprising an insulin or analoguc or derivative thereof and an enhancer; (b) adjusting the pH to a pH in the range of 4.5 to 7.4; (c) precipitating a product comprising the insulin or analogue or derivative thereof and the enhancer, wherein the precipitation is performed essentially without evaporation of the solution; and (d) removing the water.

Abstract: The present invention relates to a compound of general formula I ##STR1## for treating medical disorders related to binding to human somatostatin receptor subtypes.

Abstract: The present invention relates to variants of cyclomaltodextrin glucanotransferase. More specifically the invention relates to a method of modifying the substrate binding and/or product selectivity of a precursor CGTase enzyme, and CGTase variants derived from a precursor CGTase enzyme by substitution, insertion and/or deletion of one or more amino acid residue(s), which amino acid residue(s) holds a position close to the substrate. Moreover, the invention relates to DNA constructs encoding the CGTase variants, expression vectors, host cells and methods of producing the CGTase variants of the invention.

Abstract: The present invention relates to a method of preparing a variant of a parent lipolytic enzyme, comprising (a) subjecting a DNA sequence encoding the parent lipolytic enzyme to random mutagenesis, (b) expressing the mutated DNA sequence obtained in step (a) in a host cell, and (c) screening for host cells expressing a mutated lipolytic enzyme which has a decreased dependance to calcium and/or an improved tolerance towards a detergent or a detergent component as compared to the parent lipolytic enzyme.

Abstract: Compounds of peptide mimetic nature having the general formula I ##STR1## wherein a and b are independently 1 or 2, R.sup.1 and R.sup.2 are independently H or C.sub.1-6 alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.

Abstract: The present invention relates to mutants of a blue multi-copper oxidase, comprising (a) a substitution of one or more amino acid residues with other amino acid residues, (b) an insertion of one or more amino acid residues and/or (c) a deletion of one or more amino acid residues, wherein the substitution, insertion or deletion is carried out at a position which is located no greater than 15 .ANG. from a Type I (T1) copper site. The present invention also relates to nucleic acid constructs comprising a nucleic acid sequence encoding the mutants of the present invention, host cells comprising the construct of the present invention, and methods for producing mutants of the present invention.

Abstract: The present invention relates to novel host cells and to methods of producing proteins. More specifically the invention relates to a host cell useful for the expression of heterologous proteins, which host cell has been genetically modified in order to express significantly reduced levels of a metalloprotease. Moreover the invention relates to a method of producing a heterologous protein, which method comprises cultivating the host cell in a suitable growth medium, followed by recovery of the desired protein.

Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases.

Abstract: This invention relates to activation of enzymes. More specifically, the invention relates to agents capable of enhancing the activity of peroxidases or peroxidase acting compounds. The invention also relates to methods of oxidizing a substrate with a source of hydrogen peroxide in the presence of a peroxidase enzyme or a peroxidase acting compound, and an enhancing agent. More specifically, the invention relates to a method of bleaching of dye in solutions, to a method of inhibiting the transfer of a textile dye from a dyed fabric to another fabric when said fabrics are washed together in a wash liquor, to a method of bleaching of lignin-containing material, in particular bleaching of pulp for paper production, to a method of treatment of waste water from pulp manufacturing, and to a method of enzymatic polymerization and/or modification of lignin or lignin containing material.

Abstract: The present invention relates to Curvularia verruculosa haloperoxidases and isolated nucleic acid fragments comprising nucleic acid sequences encoding the haloperoxidases as well as nucleic acid constructs, vectors, and recombinant host cells comprising the nucleic acid sequences. The invention also relates to methods for recombinant production of the haloperoxidase. The invention further relates to compositions comprising the haloperoxidases and methods of using the compositions for killing microbial cells or inhibiting growth of microbial cells.

Abstract: A process for expression of a protein product in Aspergillus oryzae is disclosed. The process comprises transforming Aspergillus oryzae with a vector system comprising DNA sequences encoding functions facilitating gene expression, a suitable marker for selection of transformants, and a DNA sequence encoding the desired protein product. The process enables industrial production of many different polypeptides and proteins in A. oryzae. Examples of such products are chymosin or prochymosin and other rennets, proteases, lipases and amylases. Also disclosed is an effective promoter for expression of a protein in Aspergillus. A preferred promoter is the TAKA-amylase promoter or functional parts thereof. There is also provided a process for the production of a recombinant Humicola lipase. The recombinant Humicola lipase from A. oryzae differs from the native lipase in having a greater glycosylation and in exhibiting an improved thermostability.

Abstract: In vivo assays for selecting candidate therapeutics for inhibiting amyloidoses, such as congophilic and fibrillar .beta./A4 amyloid deposition in brain. A candidate reagent is administered to a first rat in a first infusate comprising .beta./A4 peptide and perlecan by continuous infusion into the hippocampus for at least one week. The candidate reagent is selected as a candidate therapeutic for inhibiting congophilic and fibrillar .beta./A4 amyloid deposition in brain if the first infusate diminishes congo red and thioflavin S staining indicative of amyloid deposition adjacent to the infusion site, as compared with a second rat receiving a second infusate consisting essentially of .beta./A4 peptide and perlecan.